Sentences with phrase «new sma»

I am one of the financial planners at Motley Fool Wealth Management and we are excited to be bringing you two new SMA strategies.

The Foundation is collaborating with biotech and pharmaceutical companies to identify new SMA - specific therapeutics.

The researchers said there are two distinct advantages of the new SMA - STM method when compared with the current technology - the Nobel Prize - winning technique called cryogenic electron tomography.

Nestlé's «NEW SMA HA Infant Milk» is the focus of a new marketing campaign targeting health workers in the UK (below, Nestlé continues to claim that its SMA HA Infant Milk is «clinically proven to reduce risk of developing cow's milk protein allergy»).

The main topic of the entire visit to Switzerland will be protein and the changes to Nestlé's new SMA PRO range.

Nestlé's event was ostensibly about «food hypersensitivity management in infants and pre-school children», but is part of its strategy to promote the SMA brand in general, and its new SMA HA formula in particular.

In 2013 it launched its New SMA First Infant Milk claiming it to be «closer to breastmilk» (below).

«Anyone using the new SMA PRO formula and concerned about how their child is reacting to it should contact their health worker and can be assured that all brands on the UK market are required to meet legal composition requirements.

Nestlé has produced a SMA - branded video on protein and is working with parenting bloggers to promote it and drive traffic to its SMA Mums website, where the new SMA PRO infant formula is promoted.

Nestlé's marketing company is attempting to set up interviews with Dr Cannon to speak on the «changing protein composition of breast milk» as part of Nestlé's new SMA PRO infant formula rollout.

Not exact matches

Nestle is launching a new formula, called SMA PRO.

And it has partnered with parenting bloggers, who direct pregnant women and new mothers to the «SMA Mums» website for information on diet during pregnancy and breastfeeding — the website promotes the infant formula (examples here).

Almost nothing positive to say re «new» SMA Pro on social media.

In 2012 it set up the SMA Baby Know How Road Show to target pregnant women and parents in shopping centres when a «new improved» formula was being launched at that time.

Left: Nestle's SMA professional know - how website, promoting SMA HA (see: Nestle launches new hypoallergenic formula promotion campaign as BMJ finally retracts fraudulent research that built the market).

In 2012, we ran a successful campaign to stop the SMA Baby Know How road show touring shopping centres in the UK to launch new ready - to - feed formula packaging.

We have been receiving reports of Nestlé's Clinical Network Representative approaching health workers inviting them to attend events on «The ins and outs of child care» — offering information on topics such as water birth (left), a free lunch and, ah yes, «New Product developments in SMA», the infant formula brand Nestlé now markets in the UK.

Danone is facing a new competitive environment in both Ireland and the UK since December 2012 when Nestlé completed its takeover of Pfizer Nutrition and its Wyeth subsidiary, the company behind the SMA brand.

Baby Milk Action / IBFAN - UK is highlighting this week that Tesco and other retailers are running special clearance displays of Nestle's SMA infant formula as the company is launching a «new improved» version.

To launch the campaign we sent out half a million «We're mums too» packs to pregnant women and new mums, illustrating the commitment of the SMA brand to them and their journey through motherhood.

«In January Nestle launched «new improved» SMA infant formula having reduced the protein level, which it says was in excess of requirements.

One such email launching SMA Pro claimed its NEW IMPROVED formula had protein profile closer to breastmilk and that existing formula gave «protein intakes in excess of requirements».

Of the 14 SMAs in New York, Ulster ranked third in job growth behind New York City and the Ithaca area.

Researchers at the University of Missouri developed a new molecule in April 2014 that was found to be highly effective in animal models exhibiting SMA.

For now, they wrote, researchers and clinicians will continue to share any new data about nusinersen use in SMA patients to inform future decisions, including how broadly treatment should be pursued.

David Magnus, PhD, director of the Stanford Center for Biomedical Ethics and professor of medicine and of biomedical ethics, said those concerns resonate beyond treating SMA patients, who represent a relatively small group of people, because competition is fierce for resources to treat patients with any number of illnesses for which new and more expensive treatments are emerging.

As promising new therapies such as those directly targeting survivor motor neuron (SMN) are entering clinical trials for infants, children, and adults with SMA, researchers are searching for biomarkers in blood that can monitor their effectiveness.

Their findings could pave the way for new treatments for spinal muscular atrophy (SMA)-- also known as floppy baby syndrome — which is a leading genetic cause of death in children.

These findings, published in Human Molecular Genetics, point to new possibilities for targeted therapy for SMA.

«Restoring mitochondrial function might be a new treatment strategy for SMA,» said Yongchao Ma, PhD, senior author and Ann Marie and Francis Klocke, MD Research Scholar, Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago.

NEW YORK, NY — October 24, 2008 — The Spinal Muscular Atrophy (SMA) Foundation, a nonprofit organization dedicated to accelerating the development of a treatment for SMA, is pleased to announce the launch of a pilot study of Biomarkers for Spinal Muscular Atrophy (BforSMA).

New York, NY and Waltham, MA — September 18, 2007 — The Spinal Muscular Atrophy Foundation and BG Medicine today announced a collaboration to discover plasma biomarkers of drug efficacy for spinal muscular atrophy (SMA), the leading genetic cause of mortality in infants and toddlers.

March 13, 2007 — Cold Spring Harbor, New York — RNA splicing antisense technology studied at Cold Spring Harbor Laboratory (CSHL) effectively corrected an mRNA splicing defect found in spinal muscular atrophy (SMA) patients, and is now ready to be tested in mouse models.

«Targeting the splicing process is a promising strategy for finding new medicines to treat SMA, and possibly other diseases,» said Marcus Rhoades, Ph.D. of the National Institute of General Medical Sciences, which partially supported Krainer's research.

SMA Patient Registry New Website is Here!

New York, NY — November 29, 2004 — The Spinal Muscular Atrophy Foundation, a nonprofit organization dedicated to finding a treatment or cure for spinal muscular atrophy (SMA)-- the leading genetic killer of infants and toddlers — announced that is has funded more than $ 15 million in research in the last 18 months.

High throughput screening in motor neurons is a new approach to identifying effective therapy for SMA, said Lee L. Rubin, PhD, Senior Vice President for Research and Development and Chief Scientific Officer for Curis, Inc., and former Professor of Anatomy and Developmental Biology and Director of the Eisai Institute at University College in London.

New York, NY — April 19, 2004 — The Spinal Muscular Atrophy Foundation today announced that it has awarded new research grants totaling $ 1.125 million to four outstanding Young Investigators specializing in research on Spinal Muscular Atrophy (SMA), the leading genetic killer of infants and toddleNew York, NY — April 19, 2004 — The Spinal Muscular Atrophy Foundation today announced that it has awarded new research grants totaling $ 1.125 million to four outstanding Young Investigators specializing in research on Spinal Muscular Atrophy (SMA), the leading genetic killer of infants and toddlenew research grants totaling $ 1.125 million to four outstanding Young Investigators specializing in research on Spinal Muscular Atrophy (SMA), the leading genetic killer of infants and toddlers.

New York, NY — January 20, 2011 — The Spinal Muscular Atrophy Foundation announces the addition of Andrew Knight, Helen Meates, Stephen Mikita, Juli Oh and Simon Prisk to the SMA Foundation Board of Directors.

This marks a welcome new stage of advancement in SMA therapeutics development — and a clear demonstration of the value of non-profit drug development activities.

Congratulations to SMA Foundation Board Member, Stephen Mikita, Esq., on his new role as a Patient Representative to the U.S. Food and Drug Administration (FDA).

New York, NY, February 21, 2012 — The Spinal Muscular Atrophy (SMA) Foundation will join the National Organization for Rare Disorders (NORD) and others around the world in observing Rare Disease Day on February 29.

NEW YORK, NY April 3, 2012 — The Spinal Muscular Atrophy (SMA) Foundation announced today the launch of a biomarker assay panel for SMA using Myriad RBM's Multi-Analyte Profiling (MAP) technology platform.

The ICC's mission is to facilitate the conduct of efficient and successful clinical trials in SMA that lead to new treatments and ultimately improve care for people living with SMA.

NEW YORK, NY May 4, 2012 — The Spinal Muscular Atrophy (SMA) Foundation congratulates the members of the Pilot Study of Biomarkers for Spinal Muscular Atrophy (BforSMA) Trial Group for the recent publication of study results in two articles published by the open - access, peer - reviewed journal, PLoS ONE.

SMA experts and investigators discussed the importance of collaborating with other nonprofit research and patient advocacy groups; targeted genetics research; and new clinical approaches in the pipeline.

Tarrytown, New York and the Spinal Muscular Atrophy (SMA) Foundation New York, NY — have extended their research agreement to establish and behaviorally phenotype transgenic in vivo models of SMA and test potential therapeutics using these models.

ICC members work to fulfill their mission, in part, by improving or developing new outcome measures for SMA.

Basel, Switzerland, South Plainfield, NJ, USA and New York, NY, USA — November 29, 2011 — Roche (SIX: RO, ROG; OTCQX: RHHBY), PTC Therapeutics, Inc. (PTC) and the SMA Foundation, announced today a licensing agreement for PTC's Spinal Muscular Atrophy (SMA) programme.

A new study implicates a key cellular mechanism as defective in SMA for the first time, providing a new lead for developing future interventions.